The response to inhaled nitric oxide in patients with pulmonary artery hypertension is not masked by baseline vasodilator use

American Heart Journal

Volumn 150, Issue 4, 2005, Pages 725-728

  Krasuski, Richard A ^a   Wang, Andrew ^b   Harrison, J Kevin ^b   Tapson, Victor F ^b   Bashore, Thomas M ^b  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BOSENTAN; DILTIAZEM; NIFEDIPINE; NITRIC OXIDE; VASODILATOR AGENT; VERAPAMIL;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT OUTCOME; VASODILATATION;

ADMINISTRATION, INHALATION; BLOOD PRESSURE; DRUG INTERACTIONS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; VASODILATOR AGENTS;

EID: 25844469688     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.10.012     Document Type: Article

References (15)

1. R.G. Tilton, T.A. Brock, and R.A. Dixon Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension Expert Opin Investig Drugs 10 2001 1291 1308
2. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
3. S. Rich, E. Kaufmann, and P.S. Levy The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments] N Engl J Med 327 1992 76 81
4. L.J. Rubin Therapy of pulmonary hypertension: targeting pathogenic mechanisms with selective treatment delivery Crit Care Med 29 2001 1086 1087
5. H. Olschewski, G. Simonneau, and N. Galie Inhaled iloprost for severe pulmonary hypertension N Engl J Med 347 2002 322 329
6. E. Michelakis, W. Tymchak, and D. Lien Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide Circulation 105 2002 2398 2403
7. V.V. McLaughlin, D.E. Genthner, and M.M. Panella Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension N Engl J Med 338 1998 273 277
8. R.A. Krasuski, J.J. Warner, and A. Wang Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology J Am Coll Cardiol 36 2000 2204 2211
9. D.L. Wessel, I. Adatia, and J.E. Thompson Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension Crit Care Med 22 1994 1611 1612
10. J. Pepke-Zaba, T.W. Higenbottam, and A.T. Dinh-Xuan Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension Lancet 338 1991 1173 1174
11. M.J. Ricciardi, B.P. Knight, and F.J. Martinez Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine J Am Coll Cardiol 32 1998 1068 1073
12. O. Sitbon, M. Humbert, and J.L. Jagot Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension Eur Respir J 12 1998 265 270
13. C.M. Hart Nitric oxide in adult lung disease Chest 115 1999 1407 1417
14. T.M. Bashore, E.R. Bates, and P.B. Berger American College of Cardiology/Society for Cardiac Angiography and Interventions Clinical Expert Consensus Document on cardiac catheterization laboratory standards. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 37 2001 2170 2214
15. I.M. Robbins, L.L. Cuiper, and C.M. Stein Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep J Appl Physiol 85 1998 731 737